Polly A. Murphy, a director at Atea Pharmaceuticals (NASDAQ:AVIR), purchased 6,100 shares of common stock on May 18, 2026, for a total value of $25,446.
The shares were acquired at a weighted average price of $4.1715, with individual prices ranging from $4.14 to $4.19. The stock currently trades at $4.25.
This transaction was reported in an amended Form 4 filing. Following the purchase, Ms. Murphy directly holds 92,145 shares.
According to Bond.az analysis, management has been aggressively buying back shares, and the company holds more cash than debt.
In other news, Atea Pharmaceuticals reported Q1 2026 earnings with EPS of -$0.57, slightly below the expected -$0.56. The company highlighted strong cash reserves and plans for its Hepatitis C and E programs.
